A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch

ABSTRACT Background: Following prescribed medication regimens is essential for the effective treatment of any medical condition. Unfortunately, patients often fail to follow recommendations, and treatment non-compliance represents a widespread, often underestimated problem, placing tremendous burden on the healthcare system. Compliance in Alzheimer's disease (AD), a chronic neurodegenerative disease typically afflicting older adults, is especially challenging. Scope: To review factors contributing to poor treatment compliance in AD, considering the prominent role caregivers often play in treatment management; and acknowledging strategic approaches, particularly modern transdermal patches, to improve compliance in this particularly susceptible population. Articles were identified by searching MEDLINE in November 2006 (search limits: 1987–2007) using the terms: compliance; Alzheimer's; treatment; and transdermal. Additional resources included bibliographies of identified articles. Findings: Strategic approaches to improving treatment compliance include: simplifying treatment regimens, using reminder packaging, and developing more patient- or caregiver-friendly modes of administration. To date, AD therapies have been administered orally. However, recent developments in alternative modes of drug delivery, such as transdermal patches, may offer effective, well-tolerated treatment options with the potential to enhance compliance. A patch containing rivastigmine (Exelon*), an established cholinesterase inhibitor, has been developed and demonstrated to have good efficacy and tolerability in patients with AD. In addition, initial caregiver experience suggests preference for the patch over oral administration. Conclusion: Transdermal patches may be an effective way to optimize treatment compliance for AD, as well as an increasing number of other chronic conditions that typically afflict the older population, offering the possibility of more sustained clinical benefits.

[1]  A. Mauro,et al.  Transdermal Treatment Options for Neurological Disorders Impact on the Elderly , 2022 .

[2]  M. Burnier,et al.  Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. , 2006, American journal of hypertension.

[3]  A. Ryan.  Medication compliance and older people: a review of the literature. , 1999, International journal of nursing studies.

[4]  R. Metcalfe.  Compliance, Adherence, Concordance – What’s in a Name? , 2005, Practical Neurology.

[5]  C. Roe,et al.  How Many Patients Complete an Adequate Trial of Donepezil? , 2002, Alzheimer disease and associated disorders.

[6]  V. Lingala,et al.  TREATMENT PERSISTENCY WITH RIVASTIGMINE AND DONEPEZIL IN A LARGE STATE MEDICAID PROGRAM , 2005, Journal of the American Geriatrics Society.

[7]  C. Paton,et al.  Administering medicines to patients with dementia and other organic cognitive syndromes , 2001 .

[8]  Jenenne A Geske,et al.  Physicians' perspectives on caring for cognitively impaired elders. , 2005, The Gerontologist.

[9]  R. Tamblyn.  Medication use in seniors: challenges and solutions. , 1996, Therapie.

[10]  R Perera,et al.  Reminder packaging for improving adherence to self-administered long-term medications. , 2006, The Cochrane database of systematic reviews.

[11]  V. Papademetriou,et al.  Therapeutic adherence in the elderly: transdermal clonidine compared to oral verapamil for hypertension. , 1991, The American journal of medicine.

[12]  Oscar L. Lopez,et al.  Survival following dementia onset: Alzheimer's disease and vascular dementia , 2005, Journal of the Neurological Sciences.

[13]  M. Gallant,et al.  The Costs of Caring: Impact of Dementia on Family Caregivers , 2001, Journal of geriatric psychiatry and neurology.

[14]  A. Sicras-Mainar,et al.  [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine]. , 2006, Revista de neurologia.

[15]  Mats Thorslund,et al.  The Appropriateness of Drug Use in an Older Nondemented and Demented Population , 2001, Journal of the American Geriatrics Society.

[16]  E. Touitou,et al.  Drug delivery across the skin , 2002, Expert opinion on biological therapy.

[17]  J. Rejas,et al.  PNL3 RETROSPECTIVE COMPARATIVE ANALYSIS OF ANTIDEMENTIA MEDICATION PERSISTENCE PATTERNS AT 3 YEARS IN SPANISH ALZHEIMER DISEASE PATIENTS TREATED WITH DONEPEZIL, RIVASTIGMINE, GALANTAMINE AND MEMANTINE , 2005 .

[18]  M. Burnier,et al.  Compliance with antihypertensive therapy. , 1999, Clinical and experimental hypertension.

[19]  E. Damsgaard,et al.  The consumption of drugs by 75-year-old individuals living in their own homes , 2000, European Journal of Clinical Pharmacology.

[20]  A. Fisher,et al.  Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. , 2001, JAMA.

[21]  L. Ereshefsky,et al.  Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice‐daily Capsules in Alzheimer's Disease Patients , 2008, Clinical pharmacology and therapeutics.

[22]  W Toenders,et al.  Patient compliance in medical practice and clinical trials. , 1992, The International journal of risk & safety in medicine.

[23]  S. Travis,et al.  Medication administration hassles reported by family caregivers of dependent elderly persons. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.

[24]  D A Hussar,et al.  Detection methods and strategies for improving medication compliance. , 1991, American journal of hospital pharmacy.

[25]  Harlan M Krumholz,et al.  Impact of medication therapy discontinuation on mortality after myocardial infarction. , 2006, Archives of internal medicine.

[26]  V. Drennan,et al.  Self-administration of medicine and older people. , 2001, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[27]  Elizabeth A. Schlenk,et al.  Effect of Personal and Cultural Beliefs on Medication Adherence in the Elderly , 2006, Drugs & aging.

[28]  J. Cramer,et al.  A systematic review of the associations between dose regimens and medication compliance. , 2001, Clinical therapeutics.

[29]  R. Verbrugge,et al.  Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost , 2005, Medical care.

[30]  E. Damsgaard,et al.  Drug therapy in the elderly: what doctors believe and patients actually do. , 2001, British journal of clinical pharmacology.

[31]  A. Lippman.  Adherence to medication. , 2005, The New England journal of medicine.

[32]  E. MacLaughlin,et al.  Assessing Medication Adherence in the Elderly , 2005, Drugs & aging.

[33]  B. Winblad,et al.  A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patch versus capsule , 2007, International journal of geriatric psychiatry.

[34]  J. Cramer.  Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. , 1998, The American journal of managed care.

[35]  D. Suh,et al.  Drug Persistency of Two Cholinesterase Inhibitors , 2005, Drugs & aging.

[36]  E. Kalso,et al.  Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain , 2001, BMJ : British Medical Journal.

[37]  G. Small,et al.  Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years , 2005, International journal of clinical practice.

[38]  R. Stewart,et al.  Medication compliance in the elderly. , 1989, The Medical clinics of North America.

[39]  C. Viscoli,et al.  Treatment adherence and risk of death after a myocardial infarction , 1990, The Lancet.

[40]  K. Holmen,et al.  Prevalence of Alzheimer's disease and other dementias in an elderly urban population , 1991, Neurology.

[41]  E. Broderick,et al.  Prescribing Patterns for Nursing Home Residents in the US , 1997, Drugs & aging.

[42]  J. Cooper,et al.  Intentional Prescription Nonadherence (Noncompliance) by the Elderly , 1982, Journal of the American Geriatrics Society.

[43]  R. Brown,et al.  Cost analysis of once‐daily ISMN versus twice‐daily ISMN or transdermal patch for nitrate prophylaxis , 1997, Journal of clinical pharmacy and therapeutics.

[44]  S. Travis,et al.  Helping family members manage medication administration hassles. , 2005, Journal of psychosocial nursing and mental health services.

[45]  A. Sicras-mainar,et al.  Análisis comparativo de los patrones de persistencia de medicaciones antidemencia en una cohorte retrospectiva de pacientes con demencia de tipo Alzheimer tratados con donepecilo, rivastigmina, galantamina y memantina en España , 2006 .

[46]  J. Amsterdam,et al.  Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. , 2002, The American journal of psychiatry.

[47]  C. MacQuarrie.  Experiences in early stage Alzheimer's disease: Understanding the paradox of acceptance and denial , 2005, Aging & mental health.

[48]  J. Orgogozo,et al.  Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease , 2007, Neurology.

[49]  J. Jefferson.  Social phobia: a pharmacologic treatment overview. , 1995, The Journal of clinical psychiatry.

[50]  L. Hutchison,et al.  Assessment of medication management by community-living elderly persons with two standardized assessment tools: a cross-sectional study. , 2006, The American journal of geriatric pharmacotherapy.

[51]  Corcoran,et al.  Polypharmacy in the Older Patient With Cancer. , 1997, Cancer control : journal of the Moffitt Cancer Center.

[52]  Mary Ann Johnson,et al.  Caregiver burden in Alzheimer's disease. , 2004, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[53]  M. Roberson.  The Meaning of Compliance: Patient Perspectives , 1992 .

[54]  L. Beilin,et al.  Predictors of medication use, compliance and symptoms of hypotension in a community‐based sample of elderly men and women , 1998, Journal of clinical pharmacy and therapeutics.

[55]  Michel Wensing,et al.  Interventions to Improve Medication Compliance in Older Patients Living in the Community , 2003, Drugs & aging.

[56]  F. Inglis.  The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. , 2002, International journal of clinical practice. Supplement.

[57]  Won Chan Lee,et al.  Drug Persistency Patterns for Patients Treated With Rivastigmine or Donepezil in Usual Care Settings , 2005, Journal of managed care pharmacy : JMCP.

[58]  J. Cramer.  Enhancing Patient Compliance in the Elderly , 1998, Drugs & aging.

[59]  Wolters Kluwer,et al.  Medication Non-Adherence in the Elderly: How Big is the Problem? , 2008 .

[60]  Anke Richter,et al.  The impact of reducing dose frequency on health outcomes. , 2003, Clinical therapeutics.

[61]  B. Winblad,et al.  Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease , 2007, International journal of geriatric psychiatry.

[62]  B. Vellas,et al.  Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.

[63]  A. Paes,et al.  Impact of Dosage Frequency on Patient Compliance , 1997, Diabetes Care.

[64]  K. Sink,et al.  Caregiver Characteristics Are Associated with Neuropsychiatric Symptoms of Dementia , 2006, Journal of the American Geriatrics Society.

[65]  S. Banks,et al.  The Effect of Cholinesterase Inhibitors on Risk of Nursing Home Placement Among Medicaid Beneficiaries With Dementia , 2006, Alzheimer disease and associated disorders.